Clinical Trials Browser

Not yet recruiting × OTHER × durvalumab × Clear all

NCT06855225 2026-04-17

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Liver Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT06824363 2026-01-30

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

Phase EARLY_PHASE1 Not yet recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07247786 2025-12-30

MIGRANT

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

NCT07146230 2025-12-24

SPRINT 2

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07226063 2025-11-10

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07122089 2025-08-14

IOSPHERE

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07012798 2025-06-10

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06998719 2025-05-31

ACCESS

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06274879 2025-01-09

Ablatio

Phase 2 Not yet recruiting

Gastrointestinal

Bile Duct Neoplasms

NCT06719336 2024-12-05

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT06650709 2024-10-23

NEOCATS

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

Phase 2 Not yet recruiting

GastrointestinalGenitourinary

Gallbladder Cancer Unresectable

NCT06530823 2024-07-31

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05484583 2022-08-05

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Phase 2 Not yet recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04465968 2020-07-10

DEEP_OCEAN

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Pancoast Syndrome